Last reviewed · How we verify

Phase 1: Etanercept

Pfizer · FDA-approved active Biologic Quality 5/100

Phase 1: Etanercept is a Biologic drug developed by Pfizer. It is currently FDA-approved. Also known as: Enbrel.

Etanercept, marketed by Pfizer, is a well-established drug in the therapeutic landscape with a key composition patent expiring in 2028. Its primary strength lies in its robust market presence and revenue generation. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic namePhase 1: Etanercept
Also known asEnbrel
SponsorPfizer
ModalityBiologic
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Phase 1: Etanercept

What is Phase 1: Etanercept?

Phase 1: Etanercept is a Biologic drug developed by Pfizer.

Who makes Phase 1: Etanercept?

Phase 1: Etanercept is developed and marketed by Pfizer (see full Pfizer pipeline at /company/pfizer).

Is Phase 1: Etanercept also known as anything else?

Phase 1: Etanercept is also known as Enbrel.

What development phase is Phase 1: Etanercept in?

Phase 1: Etanercept is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing